Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532

Evageliou N, Renfro LA, Geller J, Perlman E, Kalapurakal J, Paulino A, Dix D, Eklund MJ, Murphy AJ, Romao RLP, Ehrlich PF, Varela CR, Vallance K, Fernandez CV, Dome JS, Mullen EA. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532. Cancer. 2024 Mar 1;130(5):792-802. doi: 10.1002/cncr.35084. Epub 2023 Oct 30. PubMed PMID: 37902955; PubMed Central PMCID: PMC10993001.

The prognostic impact of positive lymph nodes (LN+) and/or singular loss of heterozygosity (LOH) of 1p or 16q were assessed in children with Stage III Favorable Histology Wilms Tumor (FHWT) enrolled on AREN0532 or AREN03B2 alone. Six hundred and thirty-five Stage III FHWT DD4A-treated patients met inclusion criteria. Event free survival (EFS), overall survival (OS) are reported overall and by LN sampling, LN status, LOH 1p, LOH 16q, and combination of LN status and singular LOH. Patients with unknown or positive combined LOH of 1p and 16q status, and AREN03B2-only patients with unknown outcomes or treatment other than DD4A were excluded.